UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data shown on the profile page to:

http://www.ucl.ac.uk/finance/secure/research/post_award
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Imaging applications of nanotechnology in cancer
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Review
  • Authors:
    Gunasekera UA, Pankhurst QA, Douek M
  • Publisher:
    SPRINGER
  • Publication date:
    09/2009
  • Pagination:
    169, 181
  • Journal:
    TARGET ONCOL
  • Volume:
    4
  • Issue:
    3
  • Print ISSN:
    1776-2596
  • Language:
    EN
  • Keywords:
    Nanotechnology, Nanoparticles, Imaging, Cancer, IRON-OXIDE NANOPARTICLES, MULTIFUNCTIONAL MAGNETIC NANOPARTICLES, RESONANCE ENERGY-TRANSFER, LOW-DENSITY-LIPOPROTEIN, IN-VIVO, QUANTUM DOTS, BREAST-CANCER, DRUG-DELIVERY, SILICA NANOPARTICLES, GOLD NANOPARTICLES
  • Addresses:
    Douek, M
    Kings Coll London
    Guys Hosp
    Div Canc Studies
    Dept Res Oncol
    London
    SE1 9RT
    England
Abstract
Consider a single agent capable of diagnosing cancer, treating it simultaneously and monitoring response to treatment. Particles of this agent would seek cancer cells accurately and destroy them without harming normal surrounding cells. Science fiction or reality? Nanotechnology and nanomedicine are rapidly growing fields that encompass the creation of materials and devices at atomic, molecular and supramolecular level, for potential clinical use. Advances in nanotechnology are bringing us closer to the development of dual and multi-functional nanoparticles that are challenging the traditional distinction between diagnostic and treatment agents. Examples include contrast agents capable of delivering targeted drugs to specific epithelial receptors. This opens the way for targeted chemotherapy which could minimise systemic side-effects, avoid damage to benign tissues and also reduce the therapeutic treatment dose of a drug required. Most of the current research is still at the pre-clinical stage, with very few instances of bench to bedside research. In order to encourage more translational research, a fundamental change is required to consider the current clinical challenges and then look at ways in which nanotechnology can address these.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Authors
Institute of Biomedical Engineering
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by